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Metformin is the first-choice drug for treatment of type 2 diabetes notably those 
associated with obesity. It does not only reduce hyperglycemia, but also possesses 
pleiotropic effects opening the pave for numerous potential clinical applications. In 
this chapter we illustrate the various mechanisms of metformin action in reduction 
of hepatic glucose output, improvement of insulin action, restoration of fat metab-
olism and gut microbiome, reduction of inflammation, upregulation of antioxidant 
enzymes, and attenuation of tumor growth. Understanding of such mechanisms 
might propose further clinical applications for metformin.
Keywords: 5′ AMP-activated protein kinase (AMPK), metformin, gluconeogenesis, 
antioxidant, mammalian target of rapamycin (mTOR), complex 1
1. Introduction
The mechanisms underlying metformin actions appear to be complex and 
responsible for the pleiotropic effects of metformin. These mechanisms remain a 
topic of considerable debate. Actually, in the last decade we moved from a simple 
picture, that metformin acts via the liver 5′ AMP-activated protein kinase (AMPK), 
to a much more complex one, reflecting its various mechanisms in different cells 
and tissues.
Since the early studies have suggested that metformin acts by inhibition of com-
plex 1 in mitochondrial electron transport chain [1] and subsequently activation of 
AMPK [2, 3], AMPK-independent targets have also been reported. These comprise 
dephosphorylation the ribosomal protein S6, suppression of mammalian target 
of rapamycin complex 1 (mTORC1) activation and signaling via Rag GTPase [4], 
attenuation of hepatic glucose 6 phosphate levels [5], suppression of redox transfer 
by mitochondrial glycerophosphate dehydrogenase (mGPD) [6], as well as modula-
tion of inflammation/oxidative stress and oncogenic signaling pathways.
2. Primary molecular mechanism
Metformin, a hydrophilic drug with Pka 12.4, cannot readily be diffuse passively 
through the cell membrane due to its existence as cation (ionized) at physiological 
pH 7.4 [7]. As hydrophilic drug it needs a carrier mediated pathway to efficiently 
pass through the cell membrane. This is facilitated by the organic cation transporter 
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1(OCT 1) [8], a member of the soluble carrier family 22 (SLC22) of membrane 
proteins. OCT1 is mostly expressed in the liver for transferring of cations including 
metformin, but also facilitates the uptake of metformin from the gut lumen to the 
interstitium [9]. Cells express OCT1 are able to facilitate cellular uptake of metfor-
min which is in consistence with its accumulation in particular targeted organelles. 
Also, other types of OCT proteins are present at apical or basolateral sites with 
different functions.
Within the mitochondria metformin accumulates in the matrix and inhibits 
complex1 electron transfer chain NADH ubiquitin oxidoreductase (NADH)  
[1, 10, 11], which promotes proton generation. This inhibition reduces NADH 
oxidation and ultimately prevents ATP production from ATP synthase. By this 
way, the ratios of AMP: ATP and ADP: ATP increase, Figure 1. Increment in 
these ratios, which accompanied with reduction in cellular energy activates the 
cellular energy sensor (house keeper enzyme) AMPK [11]. Another consequence 
of complex 1 inhibition is the higher levels of AMP, which in turn induces 
AMPK-independent effects. Moreover, metformin directly inhibits hepatic 
GPD2, the enzyme involves in substrate (glycerol) gluconeogenesis.  
Its inhibition by metformin leads to increase cytosolic redox and suppression of 
gluconeogenesis [12].
AMPK is a heterotrimeric protein complex that consists of α, β, and γ sub-
units. The α subunit represents the catalytic site that can be activated (phos-
phorylated) by liver kinase B1 (LKB1) [13] at Thr-172 [14] and also by calcium/
calmodulin-dependent protein kinase kinase β (CaMKKβ) at Thr-172 [15]. 
The β and γ denote regulatory subunits. In mammals, the γ subunits contain 
nucleotide-binding sites for AMP or ATP [16]. In case of cellular energy stress 
with low ATP, AMP or ADP directly and mutually bind to the γ subunits causing 
conformational change leading to AMPK activation. Metformin induces activa-
tion of AMPK by LBK1 pathway and also by AMP/ADP induced conformational 
changes, too. It is worth to mention that higher levels of AMP protect AMPK 
from dephosphorylation by phosphatases [17]. AMPK plays a role in several cel-
lular events, including glucose metabolism, lipid metabolism, redox regulation, 
anti-aging and anti-inflammation [18, 19].
Figure 1. 
Primary molecular mechanism of metformin action. For explanation see text.
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3. Antihyperglycemic mechanisms of action
Metformin is currently the drug of choice in treating patients with type 2 
diabetes mellitus (T2DM). Its mechanisms are still elusive. Nevertheless, it lowers 
blood glucose through multiple mechanisms. First, it inhibits intestinal absorption 
of glucose. Second, it suppresses glucose production by the liver. Third, it facilitates 
glucose uptake into tissues, thus reducing blood glucose levels enabling better 
health to pancreatic beta-cells. Finally, it improves insulin sensitivity and inflamma-
tion. The most accepted action of metformin in T2DM is inhibition of gluconeogen-
esis and reduction in hepatic glucose output (HGO).
3.1 Mechanisms to lower hepatic gluconeogenesis
Metformin is taken up into the hepatocyte via the OTC1 [20]. Due to the dif-
ference in hepatocyte pH and pka of metformin, the drug becomes ionized and 
positively charge and accumulates in the cells and, further, in the mitochondria 
to concentrations up to 1000-fold higher than in the extracellular medium [21]. 
The uptake of positively charge metformin into the mitochondria is derived by 
the membrane potentials across the plasma membrane and mitochondrial inner 
membrane (positive outside) [1], Within the mitochondria, metformin inhibits 
complex1, which reduces ATP production and increases AMP and ADP levels. One 
consequence of respiratory chain inhibition is increment in ADP:ATP ratios that 
modestly suppress gluconeogenesis as seen experimentally in cells carrying this 
process [22], and hinder the hepatocytes from synthetizing the high energy requir-
ing gluconeogenesis [23], Figure 2. Other consequence is changes in NAD+:NADH 
ratios involving in a negative impact on gluconeogenesis [10].
Criticized comments on this mechanism are based on the higher concentra-
tion (in millimole levels) on metformin required for rapid complex 1 inhibi-
tion, although experimentation in in vitro studies have shown that inhibition 
of comlpex1 in rat hepatoma (H4IIE) cells does occur at lower concentrations 
((50–100 μmol/l)) after long periods due to a slow transport of metformin across 
mitochondrial membrane [1]. This observation has been confirmed  
experimentally [24].
Figure 2. 
Mechanism of lowering hepatic gluconeogenesis by metformin (see text).
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3.2 Activation of hepatic AMPK
Metformin induced reduction in cellular energy and increment in AMP:ATP 
ratios are indicative for activation of the energy sensor AMPK by LKB1 (see primary 
mechanism). Stimulation of AMPK results in repression of anabolism (fatty acid 
and cholesterol synthesis, gluconeogenesis) and switching on catabolism (fatty acid 
uptake and oxidation, glucose uptake) [25] in order to restore cell energy hemo-
stasis and prevent cells from damage [26]. The first observation of involvement of 
AMPK in metformin action was reported in vitro of rat hepatocytes and rat liver in 
vivo [27]. Moreover, AMPK can also be activated by glucose starvation, exercise and 
metformin activated lysosomal mechanisms [28].
3.3 AMPK dependent mechanisms
Activated AMPK phosphorylates the cAMP specific 3′,5′-cyclic phosphodiester-
ase 4B (PDE4B) and activates cAMP degradation (↓cAMP) [21]. Consequently, it 
prevents the activation of cAMP-dependent protein kinase A (PKA), the enzyme 
that phosphorylates the transcription factor cAMP response element binding 
protein (CREB), and then activates CREB-CBP-CRTC2 (CREB:CRTC2) transcrip-
tion complex involving in transcription of the genes encoding the gluconeogenic 
enzymes phosphoenolpyruvate carboxykinase (PEPCK) and Glucose 6-phospha-
tase (G6Pase) [29], Figure 2. On the other hand, AMPK induces phosphorylation 
of CREB binding protein (CBP) at serine 436 leading to dissociation of the CREB-
CBP-CRTC2 transcription complex, thus repression of PEPCK and G6Pase [29]. In 
addition, AMPK or salt-inducible kinase 2 (SIK2) phosphorylates CREB-regulated 
transcriptional coactivator-2 (CRTC2), thus, inhibits its nuclear translocation and 
retains in cytoplasm [30]. Moreover, AMPK upregulates the orphan nuclear recep-
tor small heterodimer partner (SHP), that functions as transcription repressor [31] 
through competition with CRTC2 binding in CREB–CBP complex, Figure 2.
Another mechanism mediated by AMPK is inhibition of fat biosynthesis and 
activation of fat beta-oxidation, resulting in long term enhancement of hepatic 
insulin sensitivity, which is clinically relevant. Metformin-induced hepatic AMPK 
phosphorylates the isomers of acetyl-CoA carboxylase (ACC1/ACC2) at serine resi-
dues responsible for fat beta-oxidation [32]. Phosphorylation of ACC1 and ACC2 
inhibit the conversion of acetyl-CoA to malonyl-CoA resulting in reduction of liver 
lipogenesis and hepatosteatosis (fatty liver) and increment in fatty acids oxidation, 
which are factors contributing in improvement of insulin sensitivity/signaling and 
hyperglycemia. Likewise, activation of AMPK suppresses the expression of lipo-
genic genes by direct phosphorylation of transcription factors including carbohy-
drate response element binding protein (ChREBP), Figure 2, and by this means 
regresses the lipogenesis [33], Figure 2. Taken together, the role of AMPK involves 
in phosphorylation of key metabolic enzymes and transcription co-activators/fac-
tors modulating gene expression leading to inhibition of glucose, proteins and lipid 
synthesis and stimulation of glucose uptake and fatty acid oxidation.
3.4 AMPK independent mechanisms
Metformin induced a rise in AMP levels inhibits gluconeogenesis independent 
of AMPK. AMP allosterically inhibits fructose-1,6-bisphosphatase, a key enzyme of 
gluconeogenesis and AMP sensitive [34]. This action might be responsible for acute 
metformin action. In addition, AMP inhibits adenylate cyclase producing cAMP in 
response to glucagon released in starvation leading to lowering cAMP and reducing 
expression of gluconeogenesis enzymes [35], Figure 2.
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Recent proposed mechanism of increased hepatic gluconeogenesis is related to 
impaired white adipose tissue lipolysis with resultant increase in hepatic uptake of 
non-esterified fatty acids (NEFA). Hepatic beta-oxidation of NEFA can produce 
acetyl-coenzyme A (acetyl-CoA), the allosteric activator of the enzyme pyruvate 
carboxylase that is implicated in the first step f gluconeogenesis by supplying oxa-
loacetate [36]. Insulin regulates lipolysis of white adipose tissue, thereby, indirectly 
regulates hepatic gluconeogenesis [37]. Insulin resistance with inflammation in 
white adipose tissue increases glycerol turnover. Thus, metformin improves insulin 
sensitivity and reduces resistance leading to suppression of gluconeogenesis.
In addition, white adipose tissue delivers glycerol to the liver. In the liver, 
glycerol is phosphorylated. Through mitochondrial glycerol-3-phosphate dehydro-
genase (GPD2), glycerol is converted into dihydroxyacetone phosphate (DHAP), a 
component included in gluconeogenesis.
Metformin inhibits GPD2, leading to suppression of DHAP and subsequently 
gluconeogenesis in substrate (glycerol) specific manner [12]. In context of obesity 
and T2DM, inhibition of gluconeogenesis from increased supply of glycerol due 
to dysregulation of white adipose tissue may partially benefit uncontrolled type2 
diabetic patients with dysregulated white adipose tissue lipolysis [38].
As discussed above, metformin suppresses gluconeogenesis through interactions 
with regulatory process of gluconeogenesis as shown in inhibition of transcription 
(downregulation of gluconeogenic genes expression), substrate (suppression of 
glycerol induced DHAP formation) and increase cytosolic redox Figure 2.
3.5 Mechanisms in skeletal muscle
Metformin affects skeletal muscle metabolism by direct and indirect mecha-
nisms. Emphasis has been placed on the metformin’s effect to increase insulin-
stimulated peripheral glucose uptake and to reduce glucotoxicity, which indirectly 
improves muscle glucose uptake [12]. Metformin reduces gluconeogenesis and 
hepatic glucose output leads to reduce blood glucose levels in type 2 patients, which 
accompanied by improvement in insulin action. Improvement in insulin levels in 
circulation under metformin treatment attenuates the hyper-insulinemic pressure 
on insulin receptors (insensitive phosphorylated receptors) leading to upregulation 
and increase sensitivity of receptors to insulin [39]. Consequently, muscle glucose 
uptake is indirectly stimulated by metformin due to reduce insulin resistance in 
skeletal muscle and peripheral tissues.
In skeletal muscle, activation of AMPK by metformin increases proliferator-
activated receptor γ coactivator-1α (PGC-1α), which in turn stimulates glucose 
transporter 4 (GLUT4) gene transcription [40]. This mechanism induces GLUT4 
and others mitochondrial genes required for catabolism. In addition, activated 
AMPK stimulates the translocation of GLUT4 to the plasma membrane and acutely 
increase skeletal glucose uptake.
Moreover, AMPK induced phosphorylation of acetyl-CoA-carboxylase-2 
(ACC-2) results in reduce malonyl-COA, which is the inhibitor of carnitine 
O-palmitoyltransferase, leading to increase transport of fatty acids into mitochon-
dria. Thus, fatty acid-oxidation is acutely increased. It worth to mention that these 
mechanisms are regulated by PGC-1 α, which initiates many genes involved in 
AMPK functions in skeletal muscle [40], Figure 3.
3.6 Mechanism in fat tissue
Obesity has been found to be the most crucial factor for insulin resistance (IR). 
In addition, insulin sensitivity decreases with age. Therefore, glucose entry into 
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tissues, including muscle and fat, decreases, since adipocytes have fewer insulin 
receptors. Metformin improves lipid profile in patients with T2DM. Insulin resis-
tance (IR) means reduces tissue responsiveness to insulin with resultant elevation in 
insulin levels (hyperinsulinemia). Beta-cells produce more insulin, but ultimately 
fail to overcome IR with resultant loss of beta-cell function and development of 
hyperglycemia. Risk factors for IR are obesity and inactivity.
The signaling pathway connected with IR is phosphatidylinositol-3-kinase/pro-
tein kinase B protein (PI3K/PK), which also known as Akt. Akt is also important for 
translocation of GLUT4 onto the cell membrane surface of muscle and fat cells for 
glucose entry [41]. Akt inactivation or defect can lead to impairment of membrane 
transposition of GLUT4, which results in IR accompanied with hyperinsulinemia, 
hyperglycemia and cardiac impairment [42]. Metformin activates and restores the 
PI3K/Akt/GLUT4 signaling in rats with type 2 diabetes [43], thereby suppresses IR.
Metformin enhances disposal of blood glucose into skeletal muscle and fat, thus 
insulin resistance associated with diabetes is overcome. This can be translated into 
increase storage of glycogen in skeletal muscle, enhancement of fatty acid oxida-
tion and reduced lipogenesis in adipose tissue, which in general reduce the body fat 
content.
3.7 Mechanisms in the intestine
Beside the liver, the intestine is also considered as an important target for 
metformin actions. Metformin lowers blood glucose not only through the action 
in the circulation, targeting the liver and other organs, but also through one in the 
intestine. The proposed actions are increase in intestinal glucose entry mainly in 
enterocytes with anerobic utilization, resulting in reduced net glucose uptake into 
blood with enhanced lactate production [44, 45], increase in glucagon like pep-
tide-1 (GLP1) levels, increase bile acid pool within the intestine and modulation of 
microbiome [46].
Activated AMPK phosphorylates the glucose transporter 2 (GLUT2), which then 
translocated to the apical membrane of intestinal cells, mainly enterocytes, where 
it promotes glucose uptake into enterocytes [6]. Metformin increases uptake and 
utilization (anerobic) of glucose, where subsequently an increase in plasma lactate 
is resulted. In fact, the intestine and the liver are implicated in metformin-related 
Figure 3. 
Mechanism of increase muscle responsiveness by metformin (see text).
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lactate production. The effect of metformin in intestinal glucose utilization has 
been shown in positron emission tomography–computed tomography (PET-CT) 
imaging of patients treated with metformin. This imaging technique uses positron-
emitting 18F-fluorodeoxyglucose (18F-FDG), that its intestinal (mainly in the 
colon) uptake increases in metformin treated patients confirming increase glucose 
uptake and metabolism in the gut [46].
Metformin inhibits mitochondrial glycerophosphate dehydrogenase, so the 
conversion of cytosolic pyruvates to lactate is reduced [6], thus, intracellular lactate 
levels are built up and then released into the plasma. This has been proved in rat 
studies, where the hepatic portal vein has been shown as the area with the higher 
peak of plasma lactate concentrations, implicating the intestine as the main site of 
metformin-associated anerobic glucose utilization and lactate production (esti-
mated by 10% increase in intestinal lactate concentration) [47].
Another intestinal action of metformin directs to GLP-1, which is secreted from 
L cells distributed throughout the gut but concentrated in the ileum. As reported 
in mice studies, metformin increases the expression of the precursor proteins 
(pre-proglucagon and proglucagon) of GLP-1, thus potentially increasing GLP-1 
production and secretion [48]. In addition, metformin affects the enzyme degrad-
ing GLP-1, dipeptidyl peptidase-4 (DPP4) by mechanisms that are not well clari-
fied [49]. Moreover, stimulation of GLP-1 secretion can occur indirectly, via the 
bile acid pool alteration by metformin [46]. Metformin activated AMPK directly 
phosphorylates and represses bile acid sensor, the farnesoid X receptor (FXR), on 
ileal cells, which results in reduced FXR transcription activity and subsequently 
reduced sensing and ileal absorption of bile acids [50]. By its turn, the higher level 
of bile acid pool stimulates bile acid receptors TGR5 on L cells, inducing secretion 
of GLP-1 [51]. Furthermore, the consequences of reduced bile acid absorption are 
lower levels of cholesterol in patients taken chronic metformin [52] and diarrhea 
associated with metformin intolerance due to osmotic effect mediated by increased 
luminal bile slats levels [53].
The gut microbiome composition has been shown to contribute to the develop-
ment of obesity and type 2 diabetes, which implicated in a reduction in bacteria 
producing short chain fatty acids (SCFAs) such as butyrate-producing bacteria and 
an increase in opportunistic pathogens as shown in type 2 diabetics [54]. SCFAs are 
considered as important signaling metabolites that impact hepatic gluconeogenesis 
and fatty acid metabolism [55]. Metformin modulates gut microbiota and increases 
SCFAs metabolizing bacteria, which lead to suppression of hepatic gluconeogenesis, 
reduction in FFA release from adipocytes and appetite suppression via incretin [56].
Metformin alters the microbiome composition in mice and humans, where 
the bacterium Akkermansia muciniphila is increased, accompanied with associ-
ated increase in mucin-producing goblet cells as demonstrated in mice model. 
Akkermansia muciniphila can increase endocannabinoids, which improve the 
thickness of gut mucous barrier and reduce inflammation [57], and so improve 
glucose tolerance. On the other hand, an increase in such bacteria by metformin 
triggers production of short chain fatty acids butyrate and propionate, which results 
in reduction of hepatic gluconeogenesis, appetite and weight [46]. Taken together, 
alteration of microbiome composition by metformin can improve metabolic disor-
ders which needed further investigations.
4. Mechanisms of antiinflammatory/antioxidant
Beyond the glucose lowering actions, metformin can directly and indirectly 
modulate inflammation. Several experimental and clinical studies demonstrated 
Metformin - Pharmacology and Drug Interactions
8
the anti-inflammatory actions of metformin in endothelial cells (EC) and smooth 
muscle cells (SMC), monocytes, macrophages and other cell types, where it sup-
presses the main components of inflammation and restores cell functions [58, 59]. 
Since inflammation is linked to a number of clinical disorders, thus, metformin can 
possibly interfere with and ameliorate metabolic disorders, cardiovascular diseases, 
atherosclerosis, obesity cancer and aging. Although the crucial mechanisms are not 
well elucidated, accepted anti-inflammatory mechanisms of metformin, which are 
common and implicated in the before mentioned disorders are presented below.
Activation of AMPK by metformin inhibits nuclear factor kappa light-chain-
enhancer of activated B-cells (NF-κB) transcription [60]. NF-κB is a transcription 
regulator implicated in various inflammatory pathways. Metformin induced NF-κB 
inhibition suppresses inflammatory pathways, proinflammatory cytokines and 
reactive oxygen species (ROS) production [61]. Likewise, activation of AMPK-
phosphatase and the tensin homolog (PTEN) pathway by metformin suppresses 
phosphoinositide 3-kinase (PI3K)-Akt pathway that activates NF-κB in human 
vascular SMC. In this way, NF-κB is also inhibited, Figure 4. In addition, metformin 
suppresses Poly [ADP ribose] polymerase 1 (PARP-1), which functions as a coacti-
vator of NF-κB transcription to stimulate pro-inflammatory pathways. Nitric oxide 
(NO), a mediator of in nerve, immune and CVS is decreased in oxidative stress 
induced by hyperglycemia. Metformin increases NO via activation of AMPK, which 
antagonizes inflammation and ROS production [62]. As well, metformin inhibits 
the differentiation of monocytes to inflammatory macrophages [63] through activa-
tion of AMPK, which reduces the phosphorylation of signal transducer and activa-
tor of transcription 3(STAT3), Figure 4.
Inhibition of NF-κB transcription triggers consequences in different tissues. In 
macrophages, inhibition of NF-κB activation by metformin can result in reduction of 
NO, PGE2, and proinflammatory cytokines, such as IL-1β (interleukin-1 β), TNF-α 
(tumor necrosis factor - α) [64], IL-6 and IL8 (responsible for calling monocytes and 
adhesion of endothelial cells) [65]. In human adipocyte, metformin induced inhibi-
tion of NF-κB pathway leads to suppression of proinflammatory cytokine-induced 
11β-HSD1 (11 β -hydroxysteroid dehydrogenase type 1) expression [66]. 11β-HSD1 
is elevated in human adipose tissue in obesity and metabolic syndrome, generates 
active glucocorticoids and is associated with chronic inflammation. Moreover, 
Figure 4. 
Potential mechanisms of metformin to attenuate inflammation and production of reactive oxygen species.
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inhibition of NF-κB suppresses the expression of CXCL8, a cytokine responsible 
for changing the microenvironment around the tumor by attracting leukocytes and 
endothelial progenitors contributed in angiogenesis [67]. Metformin applies its anti-
inflammatory action for antifibrotic effect on heart muscle cells through activation 
of AMPK and inhibition of the pro-inflammatory mediators of the TRAF3 interact-
ing protein (TRAF3IP2) molecule, which induced by aldosterone and enhances 
production of NF-κB [68]. Furthermore, anti-inflammatory mechanisms associated 
with atherosclerosis, allergic asthma, hepatic steatosis and vascular injury have been 
ascribed to metformin but required further elucidations.
In regard of macrophages activity, activated AMPK by metformin reduces 
phosphorylation of STAT3 (signal transducer and activator of transcription 3), 
thereby, inhibits the differentiation of monocytes into inflammatory macrophages 
(M1) [69], while promotes polarization into anti-inflammatory macrophages (M2). 
These mechanisms place metformin as potential anti-inflammatory targeting 
macrophages differentiations and polarization with benefits in vascular injury, 
atherosclerosis, certain cancer and insulin resistance [63].
Further mechanism associated with anti-inflammatory actions of metformin is 
the inhibition of advance glycation end-products (AGEs) [70], which are one of the 
crucial inflammatory factor in diabetes, promoting inflammation, ROS production 
and atherosclerosis [71, 72]. In fact, during hyperglycemia accumulation of glucose 
in cells facilitates the binding of each two closest glucose molecules with each other 
to form dicarbonyl compounds, which are percussors of AGEs. AGEs bind to their 
receptors (RAGE) in different target cells including macrophages, where they pro-
mote expression of IL1, IL6, TNF α and RAGE, and activate NF-κB pathway [68], 
leading to inflammation, apoptosis and fibrotic reactions, as observed in tubular 
cells. Metformin not only binds chemically to these precursors and renders them 
inactive, thereby reduces the formation of AGEs, but also suppresses RAGE via 
activation of AMPK [73]. Altogether, metformin suppresses RAGE/NF-κB pathway, 
leading to regression of RAGE effects on macrophages and change of their surface 
markers from inflammatory (M1) to anti-inflammatory (M2) phenotype. Figure 4 
illustrates the potential anti-inflammatory mechanisms of metformin.
Beside the direct effect on proinflammatory pathways, metformin can indirectly 
reduce inflammation through metabolic consequences. Reduction in hyperglycemia 
and subsequently the weight as well as the atherogenic LDL cholesterol levels can have 
favorable effect on chronic inflammation, atherosclerosis and cardiovascular disorders.
As mentioned before, metformin inhibits mitochondrial complex 1 electron 
transfer complex chain and reduces the production of ROS, which normally formed 
by synthesis of ATP from ATP synthase. Metformin can reduce ROS through activa-
tion of AMPK which inhibits TFG- β, a potent inflammatory factor stimulating the 
production of ROS and induce endogenous antioxidants such as glutathione reduc-
tase (GSH), superoxide dismutase (SOD) and catalase (CAT) [74]. Independent of 
AMPK activation, metformin can activate antioxidant SOD and clean the damag-
ing effects of ROS in tissues. In addition, it can direct trap hydroxyl peroxide and 
activate antioxidant enzymes such as catalase, which decomposes H2O2. Reduction 
of ROS reduces IL1β [68]. Therefore, metformin has been shown to play a role in 
controlling and changing oxidative/inflammatory pathways in clinical and labora-
tory conditions through various mechanisms.
5. Antineoplastic actions of metformin
The role of metformin in treatment of cancer has been reported in various 
recent sophisticated publications. Clinical observational studies in liver, colon and 
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pancreatic cancer have demonstrated that metformin prevents and decreases the 
risk of cancer development [75]. In addition, improvement overall survival out-
comes have been reported in patients with colorectal and breast cancer [76], where 
metformin treated breast cancer patients showed a lower HER-2 positive rate and 
mortality rate than the control group [77] Besides that, metformin enhances the 
effects of anti-cancer drugs as shown in vitro and in vivo studies using vincristine, 
cisplatin, and doxorubicin [78, 79]. Altogether, the results point to involvement of 
metformin in chemotherapy as adjuvant or a potential anti-cancer candidate which 
require further experimentations.
Cancer growth and proliferation can be regressed direct and indirect by met-
formin. Metformin induced reduction in cancer growth has been shown to be 
indirect through systemic effects related to reduced blood glucose levels, improved 
insulin resistance and declined pro-inflammatory cytokines. This indirect action 
might explain the effect of metformin in several types of cancer linked to hyper-
insulinemia as a risk factor. Also, metformin directly modulates several oncogenic 
signaling pathways described in the following text.
As mentioned in different sections of this chapter, the primary mechanism of 
metformin is to inhibit the oxidative phosphorylation by blockade of complex1 in 
mitochondria in target cells. Mitochondrial energy reduction and metabolic stress 
increase the endogenous levels of reactive oxygen species (ROS) which can mediate 
the death of cancer cells depending on oxidative phosphorylation for gaining energy 
[24]. Likewise, energy stress seems to hinder cancer cells from synthesis of energy 
requiring proteins, lipids and structural elements necessary for cancer growth and 
proliferation. This action can be considered as the first step of metformin induced 
tumor regression, and growth retardation. Furthermore, deprivation of cancer 
cells from ATP activates the tumor suppressor gene LKB1 which then phosphory-
lates AMPK [80] Figure 5. AMPK regulates several signaling pathways, primarily 
via inhibition of mammalian target of rapamycin (mTOR) signaling to suppress 
tumorigenesis as follows.
Metformin is taken up into cancer cells expressing OCT1, accumulates in 
mitochondria, blocks complex 1 and activates AMPK. AMPK phosphorylates p53 
on ser15 (the tumor suppressor) which is required to start AMPK-dependent cell 
growth arrest and apoptosis [81], Figure 5. On the other hand, activated AMPK 
Figure 5. 
Mechanisms of metformin suppressing tumorigenesis.
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phosphorylates MDMX on ser 367 leading to MDMX inactivation and p53 activa-
tion [82]. MDMX and the human MDM2 are partner proteins monitor p53 in a 
negative feedback fashion and restrain its function to maintain the normal develop-
ment and function of different tissues [83]. Phosphorylation one of them results in 
inhibition of ubiquitylation (a molecular change) of p53 leading to stabilization and 
activation of p53.
Beyond the effect on p53, metformin inhibits mTOR. mTOR is a catalytic 
subunit, composes of two protein complexes, mTORC1 and mTORC2, that regulate 
cell growth [84]. Inhibition of mTOR attenuates cell proliferation [85]. Metformin 
inhibits the activation of mTOR via AMPK-dependent and -independent mecha-
nisms. By AMPK-independent way, metformin phosphorylates directly the regula-
tory associated protein (raptor) that inactivates mTOR. Likewise, metformin 
inhibits mTOR signaling by inactivating Rag GTPase [4]. On the other hand, AMPK 
directly phosphorylates the tumor suppressor tuberous sclerosis complex 2 (TSC2) 
leading to activation of complex 1 and 2, TSC1/2. TSC1/2 inhibits Rheb, which in 
turn inactivates mTOR [86] and suppresses cell proliferation.
Besides AMPK and mTOR, metformin has been shown to affect other oncogenic 
signaling pathways. Metformin suppresses Akt (protein kinase B) expression which 
is associated with increased phosphatase and tensin (PTEN, a tumor suppressor 
gene) [87]. This is considered as main mechanism via which endometrial carcinoma 
is inhibited by metformin. Additionally, metformin inhibits activation of nuclear 
factor kappa light-chain-enhancer of activated B-cells (NF-κB) and phosphoryla-
tion of STAT3 in cancer stem cells [88]. The NF-κB and STAT3 transcription factors 
are involved in mediating an epigenic switch from non-transformed to cancer cells 
as shown in breast cancer model. This action suggests that metformin inhibits the 
anti-inflammatory pathway required for transformation and cancer stem cells 
formation [88].
Further mechanism of anticancer effect of metformin is modulation of microR-
NAs (miRNAs) expression (mainly tumor suppressor miRNA) through activation 
and upregulation of the RNAase III endonuclease (DICER). DICER is one of the 
key enzymes of microRNAs biosynthesis [89]. DICER has a role in formation of 
miRNAs and in assembly of their machinery to target mRNAs for degradation 
[90]. Downregulation of DICER is oncogenic and predict poor survival in lung, 
breast and ovarian cancer [91, 92]. In addition, impairment of metformin effect in 
vitro was shown in DICER-deficient tumor cells. As shown in Figure 5, metformin 
induced upregulation of DICER leads to expression of many suppressor miRNAs 
that target mRNA of coding genes for degradation, thus effectively reducing gene 
products such as oncogenic proteins [93].
6. Mechanisms of action in PCOS
One of the pleiotropic effects of metformin is to reduce insulin resistance (IR) 
and secondary hyperinsulinemia in diabetes mellitus and several clinical conditions 
associated with hyperinsulinemia. Hyperinsulinemia is linked with the patho-
genesis of polycystic ovary syndrome (PCOS), a condition of primary ovulatory 
disfunction associated with metabolic disturbances. PCOS is the endocrine disorder 
characterized by hyperandrogenism, anovulation and infertility. Obesity further 
exaggerates IR in obese PCOS women. Importantly, IR in PCOs women is tissue 
selective, which means persistence sensitivity to insulin actions on steroidogenesis 
in ovary and adrenal gland, in face of resistance in skeletal muscle, adipose tissue 
and liver to metabolic actions of insulin. Paradoxically, in PCOS women, some tis-
sues manifest IR, while steroid-producing tissues remain insulin sensitive [94].
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Mechanisms of insulin action contributing to hyperandrogenism in PCOS are 
various. Insulin can enhance the amplitude of luteinizing hormone (LT) pulses 
to increase androgen production in theca cells [95] (similarly insulin increases 
thecal androgen response to LH through direct binding to insulin like growth 
factor − 1(IGF-1) receptors in theca cells). Also, insulin may stimulate the activity 
of ovarian cytochrome CYP17 (P450c17) and 17β-hydroxysteroid dehydrogenase 
(17βHSD) to promote androgen steroidogenesis [96]. In addition, insulin can 
decease the hepatic synthesis of steroid hormone binding globin (SHBG), which 
allows more free androgen and estrogen to be available. Finally, insulin inhibits the 
hepatic production of IGF binding protein-1 (IGFBP-1), which increases IGF-1 in 
circulation and allows greater local action [97].
Furthermore, increase androgen levels may be linked to decrease adiponectin 
secretion by adipocyte in PCOS women, thereby further increasing insulin resis-
tance and subsequently insulin levels [98]. In addition, insulin may affect female 
subcutaneous adipose tissue and generate androgen from adipocytes by increasing 
the activity of aldo-keto reductase IC3 (AKRIC3) [99].
Metformin can ameliorate all the above-mentioned actions of insulin in PCOS. 
Treatment with metformin is useful in reduction of both hyperinsulinemia and cir-
culating androgens and also restores ovarian function with the benefits of increase 
ovulation, reduce serum androgen levels and improve menstrual cyclicity.
Metformin acts directly on ovarian theca cells and suppresses androgen produc-
tion by inhibition the enzymatic activity of P450c17 and 17βHSD [100] or indirectly 
via reduction of hyperinsulinemia and IR by multiple mechanisms. It has been 
shown that the metabolic actions of metformin on cells include increase in tis-
sue responsiveness to insulin action, insulin receptor numbers in skeletal muscle 
and adipose tissue, tyrosine kinase activity and glucose uptake. Also, metformin 
decreases intestinal glucose absorption, plasma glucagon levels, gluconeogenesis 
and glycogenolysis in the liver. Most of these actions have been mediated through 
activation of AMPK cascade, which result in indirect reduction of hyperinsulinemia 
and IR the main pathogenic component in PCOS [101].
By means of anti-inflammatory/antioxidant mechanisms contributing to PCOS, 
metformin inhibits NF-kB, whose activation triggers IR and inflammation in PCOS 
[102]. Moreover, metformin increases the activity of the antioxidant enzymes 
such as catalase and CuZn superoxide dismutase, thereby, it scavenges the reactive 
oxygen species such as hydrogen peroxide (H2O2), superoxide (O2.) and hydroxyl 
(OH.) radicals, where metformin also directly reacts with the latter one [103]. More 
other related mechanisms of metformin in PCOS are still unclear and elusive.
7. Conclusion
Based on its multiple mechanisms of action and interference with signaling 
pathways, metformin represents as a promising potential drug for treating various 
medical conditions. Furthermore, the beneficial effects arising from these mecha-
nisms can be demonstrated and clarified by substantial basic experiments and 
clinical trials.
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